A Canadian bank has expanded its coverage of the marijuana sector with new ratings for a collection of established producers.

On Monday (September 23), John Zamparo, equity research analyst at CIBC Capital Markets, kicked off his coverage of Aurora Cannabis (NYSE:ACB,TSX:ACB), The Supreme Cannabis Company (TSX:FIRE,OTCQX:SPRWF) and Organigram Holdings (NASDAQ:OGI,TSXV:OGI).


The analyst awarded Supreme Cannabis and Organigram with “outperformer” ratings, while Aurora obtained a “neutral” rating for its stock.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

The analyst issued a 12 to 18 month price target for Aurora of C$7. Supreme Cannabis earned a C$2 price projection, while Organigram was awarded a C$9 target.

While Zamparo commended Aurora’s clear leading presence in the Canadian cannabis market, the analyst wants to see some improvements from the company moving forward.

“At Aurora’s valuation (second largest among the cannabis names), we wish to see greater balance sheet strength, the presence of key strategic partners or material exposure to the US CBD market,” Zamparo wrote in his note to investors.

Zamparo also issued a warning to investors for some pressure on the stock due to increased dilution for the repayment of a convertible debenture. “Further non-dilutive financing is possible, but Aurora’s credit line has already been expanded, and asset sales may be challenging to execute,” he wrote.

In his praise of Supreme Cannabis, the analyst recognized 7ACRES, the firm’s operational brand, as one of the only brands to have significantly been recognized by consumers nearly a year after adult-use legalization in the country.

“Supreme Cannabis’ focus on existing, premium-seeking consumers may be the most effective and yet somehow neglected strategy in the adult-use cannabis space,” he wrote.

Zamparo said in his view the company has the potential to be among the top five cannabis players in the next two to three years.

According to the analyst, Organigram offers one of the only reasonable prices of entry for investors to gain exposure into the sector.

The researcher said Organigram has an advantage because of investors’ preference for companies with positive earnings before interest, tax, depreciation and amortization.

“Despite being one of the earliest licensed producers (LP) in Canada, we believe Organigram suffers from relative obscurity versus its peers because of its geography and focus on execution rather than promotion,” he wrote.

Zamparo was a featured speaker at the recent MoneyShow event in Toronto. In a panel alongside Horizons ETFs Management (Canada) CEO Steve Hawkins, the analyst explored the dueling nature of the Canadian and US cannabis investment markets.

Giving a long-term projection, Zamparo said the US market will be able to leverage the power of its brand appeal at an international scale, while Canada will most likely export its knowledge based on its early start after recreational legalization in 2018.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 

Appointment of Dr. Kelmendi, Assistant Professor of Psychiatry at Yale University and co-founder of the Yale Psychedelic Science Group, brings another experienced medical professional to Lobe’s advisory team.

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the appointment of Benjamin Kelmendi, MD, Assistant Professor of Psychiatry at Yale University School of Medicine, to its Scientific Advisory Board.

Keep reading... Show less

Ayurcann Holdings Corp. ( CSE: AYUR ) (the “ Company ” or ” Ayurcann “), a Canadian extraction company specializing in the processing of cannabis and hemp for the production of oils and various derivative products, is pleased to unveil further details of its Phase 2 expansion plans.

Ayurcann has commenced trading on the Canadian Securities Exchange (” CSE “) on April 8, 2021 and subsequently announced a private placement of up to $500,000 (” Financing “), as per the Company’s press release dated April 12, 2021. The proceeds of the Financing are intended to be used to further pursue Phase 2 of the expansion of the production capacity of the Company’s Pickering facility.

Keep reading... Show less

New findings suggest the COVID-19 pandemic, combined with expanded state legalization, has attracted new consumers to the category and accelerated cannabis acceptance and adoption.

  • YouGov study indicates the number of current cannabis consumers has increased 56% within just two years compared to the 16% of Americans who reported current consumption in 2018.
  • 23% of current consumers say they tried cannabis for the first time within the past year.
  • More than half of cannabis consumers say they will purchase or try a new product or format this 420, indicating that the holiday is becoming increasingly focused on exploration and trial.

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or the “Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, released the results of a survey today showing one in four Americans currently consume cannabis, reporting they’ve tried some form of cannabis within the past twelve months. That’s a significant increase since 2018* when just 16% of U.S. adults reported current consumption, representing a 56% increase in just two years. What’s more, 23% of current cannabis consumers say they tried cannabis for the first time over the past year, suggesting the COVID-19 pandemic, combined with expanded state legalization, has rapidly accelerated cannabis acceptance and adoption in America.

Keep reading... Show less

Acquires Three Operating Dispensaries in Northeast Pennsylvania

Purchase price represents a mid-single digit multiple of KCR’s expected 2021 EBITDA

Keep reading... Show less